Status:
RECRUITING
Effects of an Exercise and Diet Program on Biochemistry and Body Composition in Patients With CKD in G1 and G2 Stages
Lead Sponsor:
University of Guadalajara
Conditions:
Kidney Diseases
Diet, Healthy
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
How Exercise, a Controlled Diet and Education Improve the Health of People with Early-Stage Renal Failure: A Study at Ciudad Guzmán Hospital
Detailed Description
Chronic kidney disease has a high mortality rate per year, which has led to the search for different intervention strategies to improve adherence to treatment and the promotion of healthy behaviors su...
Eligibility Criteria
Inclusion
- Established diagnosis of CKD by the physician in G1 and G2
- Who meet the requirements of normal or decreased filtration rate according to:
- G1: ≥ 90 or G2: 60-89 mL/ min/ 1.73m2
- Alterations in the urinary sediment (cellular cylinders of any type, dysmorphic erythrocytes).
- Confirmation of damage by renal ultrasound (Decreased renal size, thinning of the renal cortex, increased echogenicity of the parenchyma, poor differentiation between the renal cortex and sinus, renal cysts suggestive of cortical or medullary changes).
- Men and women between 18 and 65 years old
- Control of baseline pathologies (glycosylated hemoglobin less than 9%, blood pressure no higher than 140/90mmHg).
- Patients who agree to participate in the study and sign the informed consent form.
- Patients who have no limitations to perform the exercises.
- If participants have diagnosed diabetes or hypertension, who are on medication and under regular internal medicine or nephrology treatment.
- Male and female patients, including those who are illiterate but can be accompanied in the initial sessions to sign the informed consent form.
- All participants, even those who do not have a mobile device, will be provided with an exercise and nutrition guide so that they do not have any limitations when carrying out the activities.
Exclusion
- Stages 3, 4 and 5
- Children under 18 years of age
- Patients who, due to their place of origin, find it difficult to travel to the sessions.
- Diabetes Mellitus in uncontrolled (Glycated Hemoglobin \>9 %)
- Those who have lost their sight
- Presence of uremic alterations such as uremic encephalopathy.
- Who present unstable blood pressure with blood pressure levels above 140/90mmHg, patients showing sustained blood pressure elevations above 140/90 will be discontinued from the study.
- Peripheral vascular disease of all types (Peripheral Arterial Disease (PAD), Deep Vein Thrombosis (DVT), Chronic Venous Disease (CVD), Abdominal Aortic Aneurysm (AAA), Buerger's Phenomenon (Thromboangiitis Obliterans), Kawasaki Disease).
- Failure to sign the informed consent form
- Elimination Criteria:
- Injury, discomfort that makes reincorporation impossible.
- Patients who have decided to abandon the study
- Patients who do not attend 2 of the face-to-face sessions, those who do not attend two of their sessions will be taken into consideration.
Key Trial Info
Start Date :
October 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 28 2025
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT06912425
Start Date
October 1 2024
End Date
October 28 2025
Last Update
April 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro Universitario del Sur
Ciudad Guzmán, Jalisco, Mexico, 49000